Marching ahead with its platform that finds monoclonal antibody binders to allosteric sites on receptors and ligands, Xoma Corp. priced a public stock sale of 7.5 million shares at $3.62, the previous day's closing bid, as investors await Phase III data on gevokizumab for uveitis.